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ABSTRACT
Background and significance: The rebirth of the theory of immunosurveillance in 2001
rejuvenated interest in anticancer immunotherapies. In particular, T-cell-based therapies have
garnered substantial interest due to the robustness and tumor antigen-specific cytotoxicity of Tcell anticancer immune responses.
Hypothesis: The efficacy of adoptive cell transfer (ACT) T-cell immunotherapy could
significantly improve and gain widespread approval if future innovations in ACT-based
approaches account for the pro- and antitumoral properties of non-CD8+ lineages of effector Tcells, evasion of T-cell antitumor immunity, and tumor-induced suppression of antitumor
immunity.
Problem analysis: Despite numerous reports of highly successful ACT-based clinical trials, no
such therapy is currently approved by the FDA for use in cancer patients. This project explores
three limitations of current ACT-based anticancer therapies that may underline their lack of
federal approval: inadequate incorporation of the pro- and antitumoral properties of non-CD8+ Tcell lineages as potential immunotherapeutic targets; tumor evasion of T-cell antitumor
immunity; and tumor-induced immunosuppression of T-cells.
Broader implications: Substantial patient-incurred economic costs are likely to be associated
with ACT-based anticancer therapies if they are approved for clinical use. However, the
relatively few side effects associated with anticancer ACT render this approach significantly less
abusive than traditional forms of anticancer treatment.
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BACKGROUND AND SIGNIFICANCE
One of the most urgent and complicated problems that confronts modern clinical medicine is the
treatment of human cancers. Although the incidence rates of most cancers are reported to have
begun stabilizing during the past five decades and the rate of cancer deaths appears to be
experiencing a slow decline, the numbers of new diagnoses of most cancers continue to increase
each year. Even more alarmingly, the types of treatment for all forms of cancer have remained
dismally static and ineffective [1,Fig. 1]. Indeed, the three most common forms of cancer
treatment – surgical excision of tumors, ionizing radiation therapy, and cytotoxic chemotherapies
– are so remarkably primitive and impotent, yet ubiquitous and unparalleled in their clinical
applications, that they have earned a bleak moniker for themselves: “slash, burn, and poison,”
respectively. Even in light of significant advancements in the early detection of cancers, these
extremely outdated treatment options are, in general, unsuccessful in remedying the cancers of
even those persons whose diseases are detected early. The inadequacy of current treatment
regimens is evidenced by the fact that cancer claimed an estimated 590,000 lives in the United
States in 2015, while only 3 times as many new cases – about 1,660,000 cases – are estimated to
have been reported [1]. In other words, for every cancer death, about 3 new cancer diagnoses are
being made, yielding a 1:3 ratio of epidemic proportions that highlights the need for novel, more
effective treatments. Of equal concern is the abuse that a patient must endure at the hands of a
current treatment regimen: it is typical for cancer patients who have been slashed, burned, and/or
poisoned to be brought, quite literally, to their knees as the debilitating symptoms of their
treatments often equal or even eclipse the physical punishments of the cancer itself [2]. A
groundbreaking series of mouse model experiments at the turn of this century, however, finally
revealed an encouraging, effective target for innovative cancer therapies that offer potent, patient-
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friendlier alternatives to the surgeon’s unforgiving knife and the chemotherapist’s toxic
cocktails: the human immune system.
History of cancer immunobiology
The theory of the immune system’s potential role in antitumoral immunity is far from new:
German physician and scientist Paul Ehrlich postulated as long ago as the early 1900s that the
immune system is equipped with the means to protect the body from cancer [3]. At the time,
however, the complex biology of the immune system remained to be elucidated, and Ehrlich’s
experimentally unfounded theory, though enticing, was quickly dismissed. Nearly 50 years later,
as immunologists were finally armed with the means to directly study the anatomy and
physiology of the immune system, Ehrlich’s theory was resurrected by Sir Macfarlane Burnet
and Lewis Thomas, this time with a name: the immunosurveillance hypothesis [4]. Burnet and
Thomas reasoned that the adaptive arm of the immune system is capable of suppressing
tumorigenesis: they suggested that just as the lymphocyte components of the adaptive immune
system (AIS) had been shown to survey the body for exogenous contagions, those same cells –
namely B, T, and natural killer (NK) cells – are responsible for monitoring and eliminating
endogenous pathologies, including the development of neoplastic lesions. However, after several
labs challenged Burnet and Thomas’s data, the immunosurveillance hypothesis failed to obtain
experimental support once again and remained a forgotten hypothesis until the turn of the 21st
century [3].
Finally, in 2001, immunologists Vijay Shankaran, Robert Schreiber, and other colleagues
successfully provided compelling, concrete support for the existence of cancer
immunosurveillance by demonstrating that immunodeficient mice were at elevated risk of
chemically induced and spontaneous tumorigenesis compared to immunocompetent murine
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controls [5]. In their initial experiment, Shankaran et al. (2001) engineered 15 immunodeficient
mice in which they disrupted the activity of recombination-activating gene 2 (RAG2), which is
expressed only in lymphocytes and is vital to their function. Their 15 immunocompetent, wild
type mice were genetically unaltered. Both groups of mice were exposed to chemical carcinogen
methylcholnthrene (MCA) for 160 days, at which point the authors reported that only 2 of the 15
immunocompetent mice, but 9 of 15 immunodeficient mice, had formed MCA-induced tumors
[5,Fig. 2]. Perhaps more strikingly, the authors performed a second experiment to evaluate the
role of immunological tumor suppression of spontaneous tumors. After 15-16 months, all
immunocompetent and immunodeficient mice (as previously described) were killed; the authors
reported that all 11/11 immunocompetent mice were free of cancer (although 2 animals had
developed benign tumors), while all 12/12 immunodeficient mice had developed some form of
neoplastic disease [5]. Thus, the authors concluded that T-cells, B-cells, and/or NK cells (which
had been rendered inoperative by RAG2 disruption) must be essential in the immunological
suppression of chemically induced and spontaneous tumor development [5]. The ensuing flurry
of tumor immunology research spoke for itself: cancer immunosurveillance had finally graduated
from “theory” to the realm of experimental verification, marking a monumental – yet poorly
understood – addition to the field of tumor biology and rejuvenating interest in immunotherapy
as a viable form of cancer treatment.
Since the rebirth and subsequent validation of cancer immunosurveillance, an additional
theory, of which immunosurveillance is a key component, has been proposed by Schreiber et al.
(2011): the cancer immunoediting hypothesis. This hypothesis comprises three phases that
characterize the interaction of the immune system with cancer cells, the first of which, termed
the elimination phase, is essentially an updated version of Burnet and Thomas’s cancer
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immunosurveillance during which tumor cells are detected and destroyed by the immune system.
The second phase, equilibrium, describes tumor cells that survive elimination but are forced into
a sort of dormancy by the AIS, which suppresses additional tumor growth but simultaneously
“sculpts” tumor cell immunogenicity, ultimately allowing for the survival of cells that are nonimmunogenic and therefore resistant to antitumor immunity. Tumor cells that acquire means by
which they may circumvent both elimination and equilibrium enter the third phase of
immunoediting – escape – during which they emerge as aggressively malignant tumors that
escape immune detection and destruction [3]. One advantage of the immunoediting hypothesis is
that it identifies promising targets for cancer therapy. If, for example, one could therapeutically
enhance the immunosurveillance capabilities of the AIS, it follows that it may be possible to
selectively target tumor cells for destruction; concurrently “shutting off” the means by which
cancer cells escape the AIS may, in turn, amplify the efficacy of a therapeutically enhanced AIS.
However, the AIS is a complex system that comprises many different types of cellular and
molecular players, begging the question: what component (or components) of the adaptive
immune system could be targeted by cancer immunotherapy to selectively destroy cancer cells?
One contender consistently seems to rise above the rest: T-cells.
The past two decades have witnessed multiple publications that support the conclusions
of Shankaran et al. (2001) regarding the roles of effector T-cells, NK cells, and B cells1 in the
suppression and, paradoxically, the promotion of various cancers (potentially as a consequence
the aforementioned sculpting of minimally immunogenic tumor masses and/or suppression of
antitumor immunity) [5,6]. Of those different lymphocytes, T-cells in particular appear to be the

1

The classification of B cells as effector cells is disputable: many immunologists insist that because the antibody
products of B cells – and not the B cells themselves – directly interact with target cells to effect the immune
response, B cells should not be classified as effectors.
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primary effectors of cancer immunoediting, during which the immune system both combats and
is exploited by cancer. The central role of T-cells in antitumor immunity is evidenced by their
increased (and fluctuating) concentrations in the tumor microenvironment (TME) and within the
tumor itself throughout the lifetime of the tumor: such localized increases in T-cell populations,
even in classical immunity, are signs of immune system priming itself to launch a specific attack
against a pathogen (or, in this case, against transformed neoplastic cells) [7-9]. Most importantly,
certain lineages of tumor-associated T-cells have been repeatedly shown to selectively lyse
tumor cells via the same mechanisms by which they lyse bacterial cells and virally-infected host
cells [8,10,11]. As such, T-cells are widely considered to be the most attractive targets for
anticancer immunotherapy per their apparent roles as the primary effectors of antitumor
immunity.
Overview of T-cell-mediated antitumor immune response
An analysis of any type of T-cell anticancer therapy warrants a review of the general mechanism
by which a T-cell-mediated adaptive immune response (AIR) is launched, a simplified version of
which is offered here. Note that, unless otherwise stated, all discussions of T-cells throughout
this project pertain to αβ T-cells – those T-cells whose surface receptor heterodimers comprise
one α and one β peptide chain. γδ T cells, which remain poorly studied in general, are discussed
briefly below in 1c.
Central to launching any AIR, including an antitumoral AIR, is an antigenic substance – a
molecule that could be anything from a peptide sequence to a sugar – that most often exists on
the surface of the pathogenic cell that produced it2. Upon detection of a surface-expressed tumorassociated antigen (TAA) by an antigen-presenting cell (APC), the antigen is internalized by the
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Antigens may also exist in a free, soluble form.
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APC, bound to a major histocompatibility complex (MHC)3 protein, and finally “presented” on
the surface of the APC in a TAA:MHC complex. Naïve T-cells – those that have not yet met
their specific antigens – whose T-cell receptors (TCRs) are specific for a single antigenic
substance in its MHC-bound form4 circulate in the blood and lymph. Once a TCR encounters its
specific TAA:MHC complex5, various endocrine and paracrine signaling pathways instruct the
T-cell to clonally expand, producing thousands of copies of itself that are each reactive to that
same TAA:MHC complex [9,12,Fig. 3]. The TCRs of those tumor-specific T-cells will then
selectively recognize and react to any cell that expresses its particular TAA:MHC complex. A Tcell’s response to TAA:MHC recognition by its TCR depends on the lineage of that particular Tcell. The major T-cell lineages and their pro- and antitumoral functions in tumor immunity are
elaborated below in the Problem Analysis section.
Adoptive T-cell transfer (ACT) therapy
Drawing on the tumor-specific lytic capabilities of the T-cell-mediated immune response, Perica
et al. (2015) enumerate a few of the advantages of using T-cells as effectors of anticancer
immunotherapy, citing the specificity and robustness of T-cell antitumor immunity [10]. Perhaps
most appealing is the specificity of T-cell AIRs, which selectively destroy only targeted tumor
cells, thereby preserving normal, non-tumor cells – something that slashing, burning, and
poisoning all fail to do, highlighting the need for the development of novel, tumor cell-specific
anticancer immunotherapies.

3

Human MHC proteins are also referred to as human leukocyte antigen (HLA) proteins.
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TCRs are specific to a single MHC protein (which exists in two primary forms, MHC I and MHC II, each of which
has hundreds of sub-forms) and to the single antigen to which they will react. Any single αβ T-cell will only be
activated by its specific antigen that is bound to the single MHC protein to which the TCR is sensitive; that same
antigen bound to a different MHC protein, for example, will not elicit an AIR [9].
5

Several other types of recognition in addition to Ag:MHC recognition are necessary to fully activate a naïve T-cell,
a few of which are mentioned below in 2b.
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The efficacy of one such T-cell-mediated anticancer immunotherapy – adoptive T-cell
transfer (ACT) – has been tested in clinical trials for more than a decade, many of which have
reported promising results. At its core, ACT for cancer therapy involves the transfusion of T-cell
lymphocytes to enhance antitumor immunity [13-16]. T-cells (primarily CD8+ T cells, which are
capable of inducing apoptosis in their target cells, thereby killing them) are harvested from a
patient’s blood or tumor and genetically modified and/or amplified in vitro before being
reinfused back into the patient. If T-cells are harvested from a tumor, it is assumed that they are
tumor cell-specific; thus, it follows that expanding the populations of those tumor-specific Tcells allows clinicians to foster and unleash a directed attack on tumor cells.
Several modifications of ACT for cancer therapy have been described. One increasingly
popular variation involves partial ablation of lymphocytes (including T-cells) in vivo prior to
reinfusion of the cultured cells in order to temporarily overcome immunotolerance (as is
mediated by Treg cells, a unique lineage of T-cells that act to suppress other T-cell effectors of
immunity), thus providing a window of time during which reinfused CD8+ T-cells may mount an
uninhibited attack on tumor cells. This approach has been shown to significantly improve the
efficacy of anticancer ACT [13]. More recently, the remarkable successes of genetically
modified T-cell ACT trials have garnered special attention, even catching the eye of the FDA,
which noted the “breakthrough status” of these therapies (although no ACT-based anticancer
therapy for cancer is currently approved by the FDA) [10,14]. The most common therapeutic
modification of T-cells ex vivo involves the transfection of tumor-specific chimeric antigen
receptors (CARs) – which combine antibody recognition with T-cell activation – and/or tumorspecific T-cell receptors into the surfaces of harvested T-cells, thereby homing in on the cancer
cells themselves while sparing normal cells from the T-cells’ selective lysis [10,13-15,17].
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As stated above, ACT-based anticancer therapies have produced exceedingly promising
results in human clinical trials. Hinrichs and Rosenberg (2014) published a review of dozens of
such trials in which they analyzed the curative effects of ACT-based therapies that had been
reported up to the point of their publication [18]. They conclude that, in general, ACT-based
anticancer regimens are associated with a 50-60% overall response in trial patients; further,
approximately 30% of patients exhibit complete responses (remission). Perhaps even more
importantly, 95% of those patients whose cancers enter remission experience durable, ongoing
remissions that persisted for many patients for years after the publishing of their respective
trials6, which speaks to the powerful potential of therapeutically-enhanced antitumor immunity.
As a consequence of such pronounced successes, the numbers of ACT-based clinical
trials for cancer continue to increase each year. Additionally, Aranda et al. (2015) note the recent
creation of startup companies that focus on the development of new approaches to ACT-based
anticancer immunotherapy [10]. However, there remains substantial room for progress. For
example, the FDA’s refusal to approve ACT-based immunotherapy as an accessible form of
cancer treatment speaks to the inadequacies of the ACT approach that must not be ignored. This
project explores three primary limitations that must be addressed by future innovations in ACTbased immunotherapy in order to garner widespread approval as an effective, advantageous new
form of cancer treatment. The next section of this paper describes each of these limitations in
turn: inadequate incorporation of non-CD8+ T-cell subpopulations in tumor immunity, tumor
evasion of T-cell immunity, and tumor-induced immunosuppression. Overcoming these
challenges may significantly improve the efficacy of ACT-based anticancer therapies, perhaps
leading to their approval as promising new alternatives to traditional treatment options.

6

Many of the patients that exhibited such durable responses were reported to have been in remission even at the
time of the review’s publishing.
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PROBLEM ANALYSIS
One of the most glaring shortcomings of ACT-based immunotherapy for cancer is its failure to
address each of the effector subpopulations of T-cells. Although cytotoxic CD8+ T-cells are
firmly established as potent killers of cancer cells, other lineages of T-cells, many of which
augment or even suppress the cytotoxic capabilities of CD8+ T-cells, have also been shown to
participate in tumor immunity. Ignoring those other lineages limits the efficacy of ACT-based
immunotherapy. Additionally, evasion and suppression of tumor immunity, which are relatively
common characteristics of cancers (especially late-stage malignancies), can render any current
form of ACT immunotherapy entirely ineffective. Even with the development of geneticallyenhanced variations of ACT that attempt to overcome tumor evasion and suppression of
immunity, resistance to ACT-based immunotherapy trials has been consistently reported.
Underlying each of these problems – the heterogeneous (and sometimes
counterproductive) effects of certain T-cell subpopulations, tumor evasion of immunity, and
tumor suppression of immunity – is, first and foremost, the absence of critical information. What
are the roles of the other, non-CD8+ lineages of T-cells in tumor immunity? How do tumor cells
evade or suppress antitumor immune responses? This section responds to those questions with an
analysis of the progress that has been made since the turn of this century in deciphering T-cellmediated tumor immunity and how it is sidestepped and even sabotaged by cancer cells.
1. What are the roles of the major T-cell lineages in tumor immunity?
Current ACT-based approaches target only CD8+ T-cells (discussed below), which severely
limits their therapeutic potential due to the presence of other T-cell lineages in the tumor
environment which may augment or inhibit the antitumoral toxicity CD8+ T-cells. Here, six T-
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cell lineages and their roles in tumor immunity are organized into three categories: antitumoral,
protumoral, and ambiguous.
1a. Antitumoral T-cells: CD8+ cytotoxic Tc cells and Type-1 CD4+ TH1 cells
The aggressors of the T-cell family, T-cells that express the protein CD8 on their surface are
responsible for the direct cytolysis of target cells. In general, as discussed above, elevated
densities of CD8+ Tc cells at sites of neoplastic lesions are thought to recognize TAA on tumor
cells and selectively lyse those cells via the same cytotoxic mechanisms by which they destroy
exogenous pathogens [8,10,11]. Additionally, CD8+ Tc cells are known to secrete antitumoral
cytokines, the most potent of which – interferon-γ (IFN-γ) and interleukin-2 (IL-2) – are
elaborated below in the context of TH1 cells [9]. As such, high densities of CD8+ Tc cells in the
tumor and the TME are strongly associated with a positive prognosis, which includes overall
survival and/or longer disease-free survival after surgical resection of the primary tumor, for
almost all types of cancer cells [3,6,19,Fig. 4]. Indeed, that association is so pronounced that
Galon et al. introduced the “immunoscore” in 2012 as a means by which cancer survival
prognoses may be quantified – with remarkable accuracy – in terms of relative tumoral densities
of antitumoral CD8+ Tc cells and (often) protumoral Treg cells (the latter of which which are
developed below in 1c) [20].
Effective cancer immunotherapy is now believed to target the activation of CD8+ Tc cells
[21]. However, it is becoming increasingly apparent that CD4+ T-cells, which express CD4
instead of CD8 on their surfaces, are critical in the activation and regulation of said CD8+ Tc
cells, although they themselves are not effectors of direct cytolysis [9]. CD4+ TH1 cells have long
been known to govern the development and cytotoxicity of CD8+ Tc cells during immune
responses to exogenous pathogens. After nearly two decades of questioning the role(s) of TH1

11

cells in tumor immunity, it is now understood that TH1 cells, like CD8+ Tc cells, are prominent at
sites of cancer lesions and are strongly associated with positive prognoses for most cancers
[5,19,21,22,Fig. 4]. The mechanisms by which TH1 cells induce the differentiation and augment
the cytotoxicity of CD8+ Tc cells are mediated by the cytokines that they secrete, the most welldocumented of which include IFN-γ and IL-2, each of which is also secreted by CD8+ Tc cells
[8,9]. Also noteworthy, TH1 cells have been shown to polarize another type of immune cell,
tumor-associated macrophages (TAMs), to the M1 phenotype; M1 TAMs, as opposed to the
protumoral M2 type, are known to suppress the growth and metastasis of tumors [13,23,24].
Multiple studies have reported a significant decrease in the M1/M2 (antitumoral/protumoral)
ratio that worsens as patients’ cancers progress; moreover, those same studies report a strong
association of an increased M1/M2 ratio with improved survivability [24,25]. Thus, TH1 cells
indirectly enhance antitumor immunity via mediation of CD8+ Tc cell and M1 macrophage
responses.
In addition to directly initiating the development of tumor-specific CD8+ Tc cells, the
IFN-γ that is secreted by TH1 and CD8+ Tc cells is also known to bolster a tumor-specific AIR by
increasing the immunogenicity of cancer cells by upregulating surface expression of MHC
molecules, which increases the likelihood of Ag:MHC presentation to CD8+ Tc cells, thereby
encouraging tumor cell lysis7 [8,19,26]. In order to take advantage of IFN-γ-induced
immunogenicity of target cells, TH1 and CD8+ Tc cells also secrete IL-2, which stimulates the
clonal expansion and survival of activated T-cells, ultimately resulting in a robust population of
tumor-specific T-cells [27].

Other, protumoral effects of IFN-γ have been reported; however, these effects are not well-supported in the
primary literature.
7
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The future development of effective ACT immunotherapies for cancer must not neglect
to incorporate antitumoral TH1 cells. Unfortunately, however, the antitumoral properties of TH1
cells are almost always eclipsed by the efforts of a second subpopulation of CD4+ T-cells, TH2
cells, concentrations of which are similarly increased at sites of neoplastic lesions.
1b. Protumoral T-cells: Type-2 CD4+ TH2 cells
Unlike CD8+ Tc cells and TH1 cells, which are strongly associated with positive prognoses in
almost all primary literature, TH2 cells are increasingly becoming associated with negative
prognoses for many types of cancers [9,19,21,Fig. 4]. This can be explained by the fact that TH2
cells often express themselves as the protumoral antipodes of TH1 cells; indeed, the TH1/TH2
inverse relationship is so well-documented – in tumor immunity and otherwise8 – that it is often
referred to as the TH1/TH2 paradigm [9,22]. In cancer patients, the TH1/TH2 relationship
manifests as a prognostic tool: an increased TH1/TH2 ratio in the tumor microenvironment and
within the tumor itself is often associated with a more positive prognosis [22]. On the other hand,
decreased ratios of intratumoral and circulating TH1/TH2 cells have been associated with poor
prognoses, highlighting the largely protumoral characteristics of TH2 cells [22]. TH2 cells
mediate their protumoral effects through their immunosuppressive cytokines: IL-10 and
transforming growth factor-β (TGF-β). In contrast to the M1-polarizing cytokines secreted by
TH1 cells, IL-10 and TGF-β polarize TAMs to the M2 (tumor-promoting) type, again speaking to
the protumoral effects of this lineage [9]. Studies have reported that up to 70% of tumorassociated macrophages are of the M2 (protumoral) type, suggesting that populations of TH2
cells are preferentially drawn to tumor cells, where they indirectly support the development of

8

The effector CD4+ T-cell response can be polarized to favor either a T H1 cell-mediated/inflammatory response,
which is induced by elevated levels of IFN-γ, or a TH2 humoral/antibody-mediated response, which is induced by
elevated levels of IL-4. Significant differences distinguish each type of response, as is evidenced by the very
different cytokine secretions of each type, and the T H1/TH2 paradigm has implications in many disease states [9].
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the tumor via M2 polarization [28]. Finally, IL-10 and TGF-β are also known to inhibit a host of
other antitumor immunity parameters, including antigen presentation to antitumoral T-cells,
proliferation of tumor-specific T-cells, and the production of TH1 antitumoral cytokines
[13,22,23,29].
The effects of TH2 cells in tumor immunity have not yet been generalized in the majority
of primary literature due to the accumulation of reports only recently that concrete their
protumoral properties. In spite of this, the potential of TH2 cells to suppress therapeutic CD8+ Tc
immunity should not be ignored by immunotherapies for cancer and techniques should be
developed to specifically interrupt their immunosuppressive effects in order to maximize the
efficacy of ACT-based anticancer regimens.
1c. Ambiguous T-cells: Type-17 CD4+ TH17, CD4+ Foxp3+ regulatory Treg, and γδ T-cells
TH17 cells – named after IL-17, their primary cytokine product – are perhaps the least-studied Tcells in tumor immunity and even in classical immmunity; thus, relatively little is known about
their function(s) in suppressing and/or promoting tumor development and growth [9]. As a result,
it is too early to decisively categorize TH17 cells as either pro- or antitumoral for any one type of
cancer [19,22,Fig. 4].
Although it would seem that TH17 cells are not candidates for T-cell immunotherapy due
to their confusing role(s) in tumor immunity, one particularly important product of the past
decade of studying TH17 cells in the context of tumor immunity has been the establishment of a
TH17/Treg paradigm, which appears to be a promising target for cancer immunotherapy [22,34].
This idea is discussed below in the context of Treg cells.
Concentrations of regulatory CD4+ Foxp3+ T (Treg) cells, like each of the above T-cell
lineages, are significantly elevated in the peripheral blood and at the tumor sites of patients with
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many types of cancer, strongly indicating that they are involved in tumor immunity [30].
Distinguishable by their expression of the Foxp3 protein, which acts as their master regulator
(the transcription factor that controls differentiation into the Treg cell lineage), Treg cells are also
set apart from the other subpopulations of T-cells per their main function: the regulation and
shutdown of the immune system once a pathogen has been cleared from the body [9]. Given the
destructive capacity of the immune system, properly-functioning immunosuppressive Treg cells
are critical in preventing excessive tissue damage to the host. In tumor immunity, however, Treg
cells are progressively being associated with negative prognoses due to their ability to suppress
the very immune system that is equipped with the means to destroy cancer cells [7,19,31,Fig. 4].
Their primary immunosuppressive secretions – TGF-β and IL-10 – are discussed above in the
context of TH2 cell-mediated immunity [9]. Interestingly, Treg cells have even been shown to
reprogram the TME towards an angiogenic phenotype, thus contributing to tumor growth and
even metastasis [32,33]. Treg-induced suppression of tumor immunity is extensively explored
below in 3a.
Recent studies have challenged the pervasive association of Treg cells with negative
prognoses [34,35]. In a meta-analysis of gastrointestinal cancers – hepatocellular carcinoma
(HCC), colorectal cancer (CRC), and gastric cancer (GC) – Huang et al. (2014) demonstrated
that, as was expected, overall survival rates 1, 3, and 5 years following tumor resection were
significantly lower in high Treg infiltration patients with HCC and GC [34]. Surprisingly, though,
CRC patients with high levels of infiltrating Treg cells were shown to have significantly higher
survival rates 1, 3, and 5 years following tumor resection, as compared with patients with low
levels of infiltrating Treg cells [34]. Their results suggest that Treg cells may exhibit deleterious
effects in certain cancers (including HCC and GC), but not in others (including CRC). Note,
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however, that these results should be interpreted carefully as the authors’ analyses of the
prognostic value of infiltrating Treg cells did not account for the effects of other lineages of Tcells (such as protumoral TH2 cells) that could have contributed to the apparent results of the
study. In sum, the prognostic value of Treg cells remains somewhat controversial for certain
cancers; thus, future research should focus on discerning which types of cancers might benefit
from infusions of Treg cells, à la ACT, thereby individualizing antitumoral immunotherapies to
best fit a patient’s particular disease [31].
As mentioned above, a recent breakthrough in understanding tumor immunity was the
proposal of the TH17/Treg paradigm, which has largely replaced the previously described
ubiquitous TH1/TH2 relationship in its prognostic value for many cancers. Perhaps most
strikingly, recent studies have revealed strong associations between the development of lung
cancer – both small cell lung carcinomas (SCLC) and non-small cell lung carcinomas (NSCLC)
– and cytokine imbalance as a result of a skewed TH17/Treg ratio [22,34]. Thus, the TH17/Treg
paradigm should be considered a valuable target for ACT immunotherapy, especially for patients
with SCLC or NSCLC, which, together, comprise the deadliest forms of cancer in the United
States [1].
One final subpopulation of T-cells, γδ T-cells, warrants discussion due to its growing
appeal as a potential target for ACT-based immunotherapy for cancer. γδ T-cells differ
significantly from their αβ counterparts both phenotypically and mechanistically: phenotypically,
they rarely express either CD4+ or CD8+ surface proteins, and their TCRs comprise one δ and
one γ chain instead of one α and one β chain; mechanistically, most γδ T-cells do not require
Ag:MHC presentation in order to be activated, and they are known to play a prominent role in
the recognition of lipid antigens, possibly in response to heat shock proteins [9,36-38].

16

Additionally, γδ T-cells comprise only a small subset, about 5%, of circulating lymphocytes,
leaving their precise role(s) in immunity – including tumor immunity – largely unexplored [37].
However, far more antitumoral than protumoral effects of γδ T-cells have been described in
recent studies [9,36-38]. Additionally, therapeutic γδ T-cells have been shown to exhibit
significant antitumoral effects in ACT-based clinical trials, which is attributed to their ability to
recognize isopentenyl pyrophosphate, a phosphoantigen that is upregulated on the surface of
many tumor cells as a byproduct of mutation-induced dysregulation of the mevalonate pathway
[36-38]. The immunotherapeutic potential of γδ T-cells is becoming increasingly clear and is
presently the subject of numerous clinical trials as a novel effector of ACT for cancer [37,39].
The advantages of γδ T-cell-based therapy will be considered below in the context of tumor
evasion of immunity.
1d. Conclusions and potential solutions
Future approaches to ACT-based anticancer immunotherapy must not neglect to address the
effector functions of the above lineages of T-cells due to their potential for both desirable and
undesirable interactions with CD8+ Tc cells. Indeed, Chodon et al. (2015) conclude that future
trials incorporating CD8+ and CD4+ lineages are expected to elicit synergistic responses that
demonstrate considerable improvement in the durability and efficacy of ACT-based therapies
[14]. However, additional research is required to fully and concretely elucidate the different
role(s) of those CD4+ lineages in human cancers, particularly the roles of TH17 and Treg cells.
2. How do tumor cells evade immune detection and destruction?
Despite the human immune system having evolved to combat tumors, as is evidenced by the
antitumoral T-cell lineages explored above, the majority of clinically significant cancers acquire
means of evading tumor immunity. Such tumor escape mechanisms are the product of genetic
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mutations that plague cancer cells due to their marked genetic instability, which is wellestablished as one of the cornerstones of tumorigenesis and tumor survivability in the face of
various cancer therapies [4,7,40]. The hypermutability that occurs as a direct result of genomic
instability means that cancer cells are at increased risk of bearing mutations in the various genes
whose products participate in tumor immunity. Malignant genomic instability is aggravated by
the laws of natural selection, which elicit pressure on tumor cells in a sort of accelerated survival
of the fittest9, in which only those cells that possess genetic (and epigenetic) traits that allow
them to escape immune destruction are selected for survival [9,39]. Future approaches to ACTbased immunotherapy for cancer must address tumor evasion of immunity to ensure that a
therapeutically enhanced immune response is not futile.
Three of the most common of those evasive/non-immunogenic traits are discussed in this
section: loss of surface-expressed tumor-associated antigens (TAA); loss of MHC proteins,
antigen processing machinery, and/or costimulatory molecules that are necessary for antigen
recognition and subsequent immune effector cell activation; and loss of function of the IFN-γ
receptor signaling pathway by which the immunogenicity of cells is augmented.
2a. Loss of surface tumor-associated antigens
Decreased expression of several known TAAs has been associated with disease progression of
many types of cancer, with advanced tumors often expressing fewer immunogenic TAAs than
lower-grade tumors. Loss of TAA is thought to contribute to resistance to anticancer
immunotherapies because such therapies inevitably destroy only those cancer cells that do
express a target TAA, while sparing – and allowing for the survival and proliferation of – cancer
cells that have lost, or never expressed, that particular TAA [39].

“Fittest” here refers to the cancer cells’ immunogenicity; those cells that elicit strong immune responses will not be
selected for survival.
9
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Although the mechanisms that regulate the selective loss of certain TAAs are poorly
understood (aside from the fact that TAA loss is often the result of genomic hypermutability),
one phenomenon that may offer some answers is the theory of immunodominance [39,41].
Originally observed in certain viral infections that express multiple viral antigens,
immunodominance as it relates to tumor immunity describes situations in which immune
responses are controlled toward the first TAA that is encountered. It has been suggested that
tumor immune responses are activated by only one or a select few TAA, which consequently
become the dominant, preferentially immunogenic TAA, while other TAA are ignored by the
immune system and become immunorecessive (non-immunogenic). Tumors cells that do not
express that particular immunodominant TAA (say, for example, antigen “D”), but express other,
immunorecessive TAA (antigen “R”), are spared from that particular D-specific immune
response and are allowed to survive and proliferate. All of the D-expressing tumor cells, on the
other hand, will be selectively destroyed by the D-specific immune response, and the Rexpressing cells that survive will produce progeny that inherit the expression of the intact antigen
R gene, but not the intact antigen D gene. This results in a non-immunogenic tumor whose
constitutive cells have undergone widespread loss of antigen D due to immune pressure,
effectively neutering any future D-specific immunotherapies [39,41]. Due to the potential links
between immunodominance and drug resistance, future approaches to ACT-based anticancer
regimens must combine the infusion of several populations of activated T-cells, each of which
has been modified to respond to different tumor antigens. This may, in theory, prevent or at least
stall the development of resistance to such therapies while more effectively destroying the entire
tumor mass.
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On the other hand, it is also worth noting that the genomic instability and hypermutability
that characterize cancer cells may on occasion work against a tumor cell by increasing
expression of surface TAA. Multiple recent studies have shown tumor mutational burden to
improve a patient’s response to immunotherapy, suggesting that hypermutable cells may
occasionally sustain mutations that result in the expression of antigenic substances that are
recognized by the immune system [7,42,43]. This phenomenon highlights the need for
individualized anticancer regimens that account for the unique genomic landscape of a patient’s
particular disease.
2b. Loss of MHC proteins, antigen processing, and co-stimulatory molecules
Loss of human MHC class I proteins (which present antigens of intracellular origin to immune
cells) has been documented in many cancers, including melanoma, colorectal carcinoma, prostate
adenocarcinoma, SCLC, NSCLC, breast carcinoma, and renal cell carcinoma [3,8,9,36,39].
Although little unequivocal evidence has accumulated to show that complete or partial loss of
expression of MHC class I proteins contributes directly to tumor escape, because mutative loss
of MHC proteins leads to loss of TAA presentation, it is hypothesized that loss of MHC protein
expression therefore causes an overall failure of TAA to stimulate an immune response [39].
Thus, it is presumed that cancer cells that have sustained mutations in MHC genes and/or in the
genes that code for the machinery that is responsible for the intracellular processing of TAA
prior to its presentation on MHC proteins are evolutionarily favored as they are effectively able
to escape immune detection [9,39].
Finally, many advanced tumors lose expression of co-stimulatory molecules that are
necessary for the complete activation of T-cells upon recognition of Ag:MHC by a T-cell’s TCR
[9,17,39]. In addition to the specific recognition of the Ag:MHC complex by a TCR that was
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discussed above, certain co-stimulatory molecules (such as B7, which is recognized by CD28 on
the T-cell) are required to alert the T-cell to a pathogenic, non-self antigen; recognition of tumor
antigens by a T-cell without co-stimulation induces T-cell anergy, a precautionary measure by
which the host’s immune system attempts to protect itself from potentially self-reactive T-cells
[9,17,39,44].
Many tumor cells that lose expression of MHC proteins or functionality of antigen
processing machinery may fail to escape γδ T-cell-induced apoptosis because, as discussed
above in 1c, γδ T-cells do not require MHC presentation of antigen to mount an immune
response [37,39]. This makes γδ T-cells a particularly attractive target for the development of
ACT-based immunotherapies that can destroy even cancer cells that have evolved to evade
detection by other T-cell lineages. However, effective ACT immunotherapy must not rely on γδ
T-cells alone; such an approach would ignore the potent antitumoral properties of CD8+ Tc and
CD4+ TH1 cells. Thus, future innovations in ACT immunotherapy for cancer should focus on
developing techniques to engineer T-cells ex vivo that do not require Ag:MHC presentation or
activation by B7 and other co-stimulatory molecules. Of note, recent trials of ACT-based
immunotherapy using T-cells that have been modified to express a chimeric antigen receptor
(CAR) (a complex that comprises an immunoglobulin-like antigen receptor and co-stimulatory
molecules, essentially eliminating the need for activation by co-stimulation) have reported
significant success [14,15]. Clinical trials involving CAR-modified T-cell anticancer treatments
have been particularly effective in the treatment of lymphoblastic leukemias due to the
attractiveness of CD19 – which is predominantly expressed on normal and transformed B-cells –
as a therapeutic target antigen for CARs; these clinical trials have reported positive responses in
60-90% of patients [16]. As a result of the remarkable efficacy of these trial therapies, CAR-
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modified T-cell therapies are being developed for solid tumors as well. These approaches are
relatively new and few reports of their effecacy are yet available, although Pule et al. (2008) and
Louis et al. (2011) have reported early signs of success in the treatment of neuroblastoma
[45,46].
2c. Loss of function of the IFN-γ receptor signaling pathway
As mentioned above in 1a, IFN-γ is one of the major effector molecules of antitumor immunity
per its ability to upregulate the surface expression of MHC molecules on which TAA is
presented to CD8+ Tc cells [9]. However, an emerging characteristic of many advanced, nonimmunogenic cancer cells is the loss of function of one or more components of the IFN-γ
receptor signaling pathway, including the partial or total loss of the IFN-γ receptor itself
[4,9,26,39]. The loss of function of at least one component of the IFN-γ signaling pathway was
recently shown to be present in at least one-third of melanoma and lung adenocarcinoma cell
lines [26]. Additionally, it has been shown that mice that do not exhibit a functional IFN-γ
signaling pathway are at much higher risk of carcinogen-induced cancers, including sarcomas,
lymphoma, and epithelial tumors, suggesting a strong association between loss of IFN-γ
signaling and survivability [39].
It must be noted that the IFN-γ signaling pathway alone does not appear to be an
advantageous target for cancer immunotherapy due to the results of recent studies that have shed
light on a potential “dark side” of IFN-γ. These studies concluded that IFN-γ may exhibit striking
protumoral effects, potentially by inducing apoptosis of certain immune cells in some human
cancers [26]. Indeed, multiple trials of IFN-γ-based immunotherapies during the 1990s reported
significant deleterious side effects associated with the therapies; the patients of one trial fared so
poorly compared to untreated patients that the trial was terminated early [47,48]. Therefore,
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while it is clear that IFN-γ signaling usually augments the antitumoral properties of the immune
system, it is unlikely that intravenous administration of IFN-γ will be approved for the treatment
of human cancers due to the potential for unwanted side effects.
2d. Conclusions and potential solutions
Few, if any, variations of ACT-based immunotherapy to resolve the phenomenon of
immunodominance have been explicitly described. However, as mentioned above, it may be
worthwhile to develop ACT-based regimens that respond to a variety of tumor-associated
antigens, potentially eliminating the possibility of evolutionarily/therapeutically selecting for the
survival of select cancer cells that do not express a single particular TAA and ensuring complete
lysis of a tumor mass. In addition to CAR-engineered T-cells that do not require co-stimulation,
the efficacy of γδ T-cells is being tested in patients whose cancers have mutated to lose Ag:MHC
presentation [14,37,39]. Together, these approaches are promising improvements to ACT-based
anticancer therapies. Indeed, Aranda et al. (2015) note optimistically that CAR-modified T-cell
immunotherapies are so effective that they are likely to be the first forms of ACT-based
anticancer therapies to be approved by the FDA for use in human cancers [10]. However, the
problematic loss of function of IFN-γ signaling remains unaddressed in current approaches.
3. How do cancer cells induce and maintain suppression of tumor immunity?
In addition to evading detection and destruction at the hands of tumor immunity, the majority of
cancer cells are also able to suppress the immune system. These two phenomena – immune
evasion and immunosuppression – are not differentiated in the majority of the current literature;
however, each strategy involves significantly different mechanisms and outcomes (though some
overlapping pathways certainly do exist). Furthermore, the proposed “solutions” to tumor

23

evasion and tumor immunosuppression differ significantly; therefore, for the purposes of this
paper, evasion and suppression are treated as separate concerns.
This section explores the two most prominent immunosuppressive strategies employed
that are by cancer cells: exploitation of Treg cells to over-suppress the very immune system of
which they are key components; and tumoral secretions of immunosuppressive molecules.
Finally, an emerging hypothesis of indirect immunosuppression by TME-associated hypoxia is
briefly acknowledged.
3a. Exploitation of Treg cell-induced immunosuppression
Treg-induced suppression of antitumor immunity exemplifies the paradoxical role(s) of the
immune system in both the suppression and the promotion of tumors. As was summarized above
in 1c, Treg cells are the primary effectors of immunosuppression in normally-functioning systems
and it is increasingly apparent that cancer cells are often equipped with the means to hijack the
“normal” immunosuppressive capabilities of Treg cells to induce aberrant, deleterious
immunesuppression [22,29-32,35,40,49-53]. Thus, one mechanism by which cancer cells may
suppress tumor immunity involves recruiting significant concentrations of Treg cells to the site of
lesions; indeed, Treg cells have been found to account for as much as 60% of all tumor-infiltrating
CD4+ T-cells in some cancers, suggesting that they must be preferentially drawn to cancer cells
[49]. At least three explanations for such drastic concentrations of intratumoral Treg cells have
been described: first, chemokines (molecules that mediate chemotaxis – the movement of cells
along chemical “paths”) released by tumor cells may cause preferential migration of Treg cells to
the site of the tumor; second, cocktails of cytokines released by tumor cells may facilitate
uncontrolled proliferation of Treg cells; third, tumor cells may release certain cytokines that drive
the conversion of conventional, non-regulatory CD4+ TH cells into CD4+ Foxp3+ Treg cells

24

[22,30,32,50,51. In addition to increased numbers of Treg cells at sites of tumor growth, enhanced
potency of those intratumoral Treg cells (as compared to circulating Treg cells) has also been
reported, though the mechanisms that may account for such a phenomenon remain wholly
unclear [30]. But how do these hyper-suppressive Treg cells work in favor of the tumor cells that
recruit them? The answer is multifold.
The primary means by which Treg cells “turn off” the immune system is through their
immunosuppressive secretions, including TGF-β, IL-10, and prostaglandin E2 (PGE2)
[3,9,35,39]. The immunosuppressive effects of TGF-β and IL-10 include: hindering the
differentiation of the antitumoral TH1 cell lineage; suppressing the cytotoxicity of CD8+ Tc cells
(potentially by decreasing production of granzyme B, a protease released by CD8+ Tc cells that
induces apoptosis of target cells); and decreasing antigen presentation by target cells (including
cancer cells) [3,22,23,39,49,50,52]. PGE2, on the other hand, upregulates the secretion of IL-10,
selectively suppresses antitumoral effector TH1 cells, and promotes the protumoral functions of
TH2, TH17, and Treg cell lineages [54]. However, the protumoral immunosuppressive capabilities
of Treg cells extend beyond their secretory molecules. For example, Treg cells have been shown to
consume and sequester IL-2, a cytokine that is critical for maintaining the functions of other Tcell lineages that are involved in tumor immunity [3,49]. Finally, most Treg cells express surface
proteins CD39, an enzyme that is responsible for the conversion of ATP and ADP to cAMP, and
CD73, which catalyzes cAMP to adenosine, a powerful immunosuppressive molecule that
disrupts the normal functions of T-cells and other effectors of immunity [30,35,49].
3b. Tumoral secretions of immunosuppressive molecules
In addition to capitalizing on the immunosuppressive features of Treg cells, cancer cells
themselves are also known to secrete multiple immunosuppressive agents, many of which
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overlap with the secretions of Treg cells. For example, tumor cells have also been shown to
secrete TGF-β, IL-10, and PGE2, thereby augmenting the immunosuppressive activities of
recruited Treg cells [9,21,39,40,51]. (Note that TGF-β is the primary cytokine that induces
differentiation of naïve T-cells into mature Treg cells, thus accounting for one of the ways by
which Treg cells are thought to preferentially accumulate at sites of tumor growth) [9,51].
Additionally, and somewhat controversially, it has been suggested that certain high-grade tumor
cells express and may even secrete apoptosis stimulating fragment ligand (FasL), which induces
apoptosis upon binding to its receptor (FAS) on target cells. This “tumor counter-attack”
hypothesis suggests that FasL+ tumor cells are capable of suppressing tumor immunity by
inducing apoptosis in FAS+ lymphocytes (including FAS+ T-cells) [10,39,55]. However, the
quality of many of the studies that proposed the tumor counter-attack hypothesis have been
questioned, and additional research has found little or no evidence of significant FasL expression
by tumor cells [41]. One hypothetical approach to manage FasL-mediated immunosuppression is
to manipulate T-cells in vitro to knockout expression of the FAS receptor. At this time, no trials
incorporating such FAS-modified T-cells have been reported.
3c. Indirect immunosuppression by TME-associated hypoxia
Finally, recent studies involving T-cell metabolism and the TME have introduced the intriguing
theory of TME-associated hypoxia-induced immunosuppression [23,56]. Building onto the wellestablished observation that tumor growth tends to result in a hypoxic TME as malignant cells
rapidly outgrow their angiogenic blood supply, it has been suggested that tumor-associated
hypoxia may create a hostile TME in which T-cells and other lymphocytes cannot thrive due to
their metabolic needs, leading to an impaired immune response. Indeed, Egebald et al. (2008)
reported that the migration of T-cells into tumor tissues is dependent on normoxic conditions,
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suggesting that an inevitable consequence of tumor cells’ hyperproliferative biology may
indirectly suppress the antitumoral immune system [22,57].
Although relatively few reports of TMA-assocaited hypoxia-induced immunosuppression
have been published, the expression of certain hypoxia-related molecules, such as HIF-1α
(hypoxia-inducible factor), has been tentatively linked to T-cell suppression in the TME. Carraro
et al. (2007) reported that effector T-cells that had been exposed to hypoxic conditions increased
the expression of HIF-1α – a transcriptional regulator – which ultimately resulted in apoptosis of
the T-cells [58]. However, the results of other studies demonstrated precisely the opposite,
reporting that increased expression of HIF-1α in T-cells was associated with prevention of
apoptosis [59]. Due to this confusion, focused studies to examine the possibility of TMEassociated hypoxia-induced immunesuppression via HIF-1α-induced apoptosis are warranted to
determine the potential role of TMA-associated hypoxia in the suppression (or the improvement)
of ACT-based T-cell infusions [23,56].
3d. Conclusions and potential solutions
Given the various means by which tumor cells attract and subsequently exploit Treg cells to
suppress tumor immunity, it is clear that future innovations in ACT-based immunotherapies
should focus not only on maximizing concentrations of CD8+ Tc cells, but also on minimizing
concentrations of Treg cells, depending on a patient’s particular cancer. Otherwise, any attempts
to therapeutically enhance a CD8+ Tc antitumor immune response may be ineffective. Mockler et
al. (2015) report that therapeutic suppression of Treg cells alone has not produced significant
clinical results; on the other hand, Chodon et al. (2015) note that CD8+ Tc-based ACT trials have
reported “spectacular” results, although the responses are short-lived due to effector suppression
[14,56]. Together, these reports highlight the need to combine Treg suppression with CD8+ Tc-
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based ACT; however, no such approaches (other than the previously described nonspecific
ablation of lymphocytes prior to reinfusion of enhanced T-cells) have been reported.

BROADER IMPLICATIONS
In conclusion, although ACT-based immunotherapy for cancer has demonstrated encouraging
results in clinical trials for human cancers, the efficacy of this novel form of anticancer therapy
will inevitably plateau in most patients if researchers and clinicians overlook the effects of nonCD8+ T-cell lineages and the challenges of tumor evasion and tumor suppression of T-cell
antitumor immunity. Future innovations in ACT-based approaches must address these challenges
in order to ensure maximum efficacy of a therapeutically enhanced adaptive immune response to
cancer.
Aside from the three problems described above, it is important that any discussion of an
anticancer therapy does not fail to address its true goal: the safe and successful treatment of
persons. A premium should be placed on translational medicine that considers what a patient is
to endure at the hands of any therapy that appears to be effective in the lab. What does ACTbased anticancer immunotherapy mean for the patients that receive it? Is it cost-effective? Is it
safe? Although these therapies appear to increase survival rates, what is their effect on the
quality of a patient’s life? That is, will ACT-based approaches render patients incapacitated and
unable to work or play, as do many chemotherapeutic regimens? Will patients be able to leave
the hospital at all? These questions, although not biological in nature, should not be discounted
in any project such as this one. As such, this final section considers the broader, person-centered
implications of T-cell-based ACT anticancer therapies.
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Economic cost
At this time, it is difficult to estimate the costs of ACT-based anticancer immunotherapies due to
the fact that all current trials are conducted at academic medical centers; thus, all costs are
reimbursed and the recipients of these experimental therapies do not incur charges. However,
Perica et al. (2015) note that the costs of ACT-based approaches may be comparable to
hematopoietic stem cell transplantation (HSCT) fees due to the technical similarities of the two
processes. HCST fees range from $36,000 to $88,000 for autologous transplants, and $96,000 to
$204,000 for allogenic transplants [13]. Unfortunately, this means that a cancer patient requiring
multiple ACT-based-transfusions could quickly amass medical debt that climbs well into the
hundreds of thousands of dollars. Such staggering costs are associated with the labor-intensive,
technological demands of these therapies. Each ACT-based regimen must be individualized to
specifically counteract each patient’s respective disease by engineering T-cells to respond to the
TAAs that are expressed by a particular patient’s tumor cells. Thus, universalization of an
antitumoral T-cell response that may be administered to more than one cancer patient does not
appear to be within reach [13]. However, it is clear that if translational ACT-based regimens are
to be commonplace in the future, emphasis should be placed on reducing their extreme costs in
order to maximize accessibility. Emerging strategies to address this issue include the
cryopreservation of expanded populations of engineered T-cells so that patients need not undergo
extraction of T-cells prior to each course of treatment [14].
Finally, patients may incur economic costs that are extraneous to the ACT procedure
itself. The majority of trial patients who receive ACT-based regimens also receive
lymphodepleting full-body irradiation and/or chemotherapy, both of which have been reported to
drastically improve therapeutic response by obliterating suppressive lymphocytes prior to
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reinfusion of modified T-cells. Unfortunately, such procedures require prolonged hospitalization
due to the devastating side effects that are generally associated with irradiation and
chemotherapy [13,14]. Thus, it is assumed that patients are generally unable to work, thereby
incurring additional financial burden.
Side effects and other non-economic considerations
Although relatively few side-effects have been reported in cancer patients undergoing ACT
treatments, it is important that patients and clinicians alike be aware of the potential adverse
effects that may occur during the course of treatment. The primary side effect that has been
reported is cytokine release syndrome, which is characterized by fever, hypotension, and even
respiratory insufficiency. This syndrome occurs as the result of extremely elevated levels of Tcell cytokine secretions post-reinfusion. Management of these symptoms includes cytokine
receptor antagonists and intensive, supportive hospital care [14]. Additionally, despite efforts to
engineer T-cells ex vivo to selectively respond to and lyse tumor cells, certain TAAs may be
expressed on normal cell populations from which the malignant cells were born, resulting in nontumor tissue damage; however, such autoimmune reactions are rare and most ACT-trials are
reported to be well-tolerated and safe [10,16]. Finally, as mentioned above, many patients
experience chemotherapy and irradiation-related symptoms during lymphodepletion prior to Tcell re-infusion. However, ACT-based lymphodepletion is only performed once in the majority
of patients, rendering it far less abusive overall than traditional repetitive chemotherapy and
radiation therapy. As such, the aforementioned therapeutic and economic challenges of current
ACT-based anticancer approaches should be given considerable attention by researchers in the
hope of making patient-friendly treatment options widely available to patients in the future.
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FIGURES

Figure 1. Graph of gender-specific (blue and pink) and overall (orange) rates of cancer incidence
and mortality in the United States from 1975-2011. Approximately one cancer death occurs per
every three new diagnoses [1].
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Figure 2. Results of an experiment by Shankaran et al. (2001) in which immunocompetent (WT)
and immunodeficient (RAG2-/-) mice were evaluated for development of malignant sarcomas
after exposure to chemical carcinogen methylcholanthrene (MCA) for 160 days.
Immunodeficient mice were significantly more prone (~60%) to the development of sarcomas
than were immunocompetent mice (~15%), confirming the role of the immune system in the
suppression of cancers [5].
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Figure 3. Schematic of a typical T-cell receptor (TCR; shown in yellow/orange in middle)
specifically interacting with an Ag:MHC complex (shown at top; antigen is green, MHC is blue).
Purple domains of TCR denote structural and intracellular signaling components. “Co-receptor”
refers to the CD8 or CD4 protein on the T-cell surface that specifically recognizes the type of
MHC proteins [12].
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Figure 4. An analysis by Fridman et al. (2012) of 124 published articles regarding the prognostic
impacts of 5 distinct T-cell lineages: CD8+ Tc (CD8+ CD45RO+), TH1, TH2, TH17, and Treg. Bars
indicate respective numbers of articles that reported good (green), poor (orange), and
inconclusive (purple) prognostic associations for each lineage of T-cell [19].

34

REFERENCES
1. Seigel R, Miller K, Jemal A. 2015. Cancer statistics, 2015. CA Cancer J Clin 65(1): 5-29.
2. Mukherjee S. 2010. The emperor of all maladies: a biography of cancer. New York:
Scribner; p 40, 165, 210.
3. Schreiber RD, Old LJ, Smyth MJ. 2011. Cancer immunoediting: integrating immunity’s roles
in cancer suppression and promotion. Science 331(6024): 1565-70.
4. Dunn GP, Old LJ, Schreiber RD. 2004. The immunobiology of cancer immunosurveillance
and immunoediting. Immunity 21(2): 137-48.
5. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. 2001.
IFNγ and lymphocytes prevent primary tumour development and shape tumour
immunogenicity. Nature 410(6832): 1107-11.
6. Kim R, Emi M, Tanabe K. 2007. Cancer immunoediting from immune surveillance to
immune escape. Immunology 121(1): 1-14.
7. Quigley DA, Kristensen V. 2015. Predicting prognosis and therapeutic response from
interactions between lymphocytes and tumor cells. Mol Oncol 9(10): 2054-62.
8. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. 2002. Cancer immunoediting: from
immunosurveillance to tumor escape. Nat Immunol 3(11): 991-98.
9. Parham P. 2015. The immune system. 4th ed. The United States of America; Garland
Science; p 113, 213-28, 347-50, 516-19.
10. Aranda F, Buqué A, Bloy N, Castoldi F, Eggermont A, Cremer I, Hervé Fridman W,
Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Lorenzo G. 2015. Trial
watch: adoptive cell transfer for oncological indications. Oncoimmunology 4(11): e1046673.
11. Humphries C. 2013. Adoptive cell therapy: honing that killer instinct. Nature 504(7580):
S13-15.
12. Gascoigne NRJ. 2008. Do T cells need endogenous peptides for activation? Nat Rev
Immunol 8(11): 895-900.
13. Perica K, Vaerla JC, Oelke M, Schneck J. 2015. Adoptive T-cell immunotherapy for cancer.
Rambam Maimonides Med J 6(1): e0004.
14. Chodon T, Koya R, Odunsi K. 2015. Active immunotherapy of cancer. Immunol Invest
44(8): 817-836.

35

15. June CH. 2007. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117(6): 146676.
16. Jeanbart L and Swartz MA. 2015. Engineering opportunities in cancer immunotherapy. P
Natl Acad Sci USA 112(47): 14467-72.
17. Sharpe M and Mount N. 2015. Genetically modified T cells in cancer therapy: opportunities
and challenges. Dis Model Mech 8(4): 337-350.
18. Hinrichs CS and Rosenberg SA. 2014. Exploiting the curative potential of adoptive T-cell
therapy for cancer. Immunol Rev 257(1): 56-71.
19. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. 2012. The immune contexture in human
tumours: impact on clinical outcome. Nat Rev Cancer 12(4): 298-306.
20. Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto
PA. 2012. The immune score as a new possible approach for the classification of cancer. J
Transl Med 10: 1.
21. Wesa AK, Mandic M, Taylor JL, Moschos S, Kirkwood JM, Kwok WW, Finke JF, Storkus
WJ. 2014. Circulating Type-1 anti-tumor CD4+ cells are preferentially pro-apoptotic in
cancer patients. Front Oncol 29: 266.
22. Duan MC, Zhong XN, Liu GN, Wei JR. 2014. The Treg/Th17 paradigm in lung cancer. J
Immunol Res 2014: 730380.
23. Egebald M, Nakasone ES, Werb Z. 2010. Tumors as organs: complex tissues that interface
with the entire organism. Dev Cell 18(6): 884-901.
24. Yuan A, Hsiao YJ, Chen HY, Chen HW, Ho CC, Chen YY, Liu YC, Hong TH, Yu SL, Chen
JJW, Yang PC. 2015. Opposite effects of M1 and M2 macrophage subtypes on lung cancer
progression. Sci Rep 5: 14273.
25. Zhang M, He Y, Sun X, Li Q, Wang W, Zhao A, Di W. 2014. A high M1/M2 ratio of tumorassociated macrophages is associated with extended survival in ovarian cancer patients. J
Ovarian Res 7:19.
26. Zaidi MR, Merlino G. 2011. The two faces of interferon-γ in cancer. Clin Cancer Res 17(19):
6118-24.
27. McCluskey J. 2011. Update on T-cell immunity: implications for tumor immunology. AsiaPac J Clin Onco 7(suppl. 1): 3-8.
28. Ma J, Liu L, Che G, Yu N, Dai F, You Z. 2010. The M1 form of tumor-associated
macrophages in non-small cell lung cancer is positively associated with survival time. BMC
Cancer 10: 112.
36

29. Tan W, Zhang W, Strasner A, Grivennikov, Cheng JQ, Hoffman RM, Karin M. 2011.
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through
RANKL-RANK signaling. Nature 470(7335): 548-53.
30. Jie HB, Gildener-Leapman N, Srivastava RM, Gibson SP, Whiteside TL, Ferris RL. 2013.
Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck
cancer patients. Br J Cancer 109(10): 2629-35.
31. Chang C, Wu SY, Kang YW, Lin KP, Chen TY, Medeiros LJ, Chang KC. 2015. High levels
of regulatory T cells in blood are a poor prognosis factor in patients with diffuse large B-cell
lymphoma. Am J Clin Pathol 144(6): 935-44.anb
32. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. 2013. Inflammation-induced
cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer
13(11): 759-771.
33. Ondondo B, Jones E, Godkin A, Gallimore A. 2013. Home sweet home: the tumor
microenvironment as a haven for regulatory T cells. Front Immunol 4: 197.
34. Huang Y, Liao H, Zhang Y, Yuan R, Wang F, Gao Y, Wang P, Du Zhi. 2014. Prognostic
value of tumor-infiltrating Foxp3+ T cells in gastrointestinal cancers: a meta analysis. PLOS
ONE 9(5): e94376.
35. Whiteside TL. 2014. Regulatory T cell subsets in human cancer: are they regulating for or
against tumor progression? Cancer Immunol Immunother 63(1): 67-72.
36. Wesch D, Peters C, Siegers GM. 2014. Human gamma delta T regulatory cells in cancer: fact
or fiction? Front Immunol 5: 598.
37. Gogoi D and Chiplunkar SV. 2013. Targeting gamma delta T cells for cancer
immunotherapy: bench to bedside. Indian J Med Res 138(5): 755-61.
38. Marquez-Medina D, Salla-Fortuny J, Salud-Salvia A. 2012. Role of gamma-delta T-cells in
cáncer. Another opening door to immunotherapy 14(12): 891-5.
39. Khong HT, Restifo NP. 2002. Natural selection of tumor variants in the generation of “tumor
escape” phenotypes. Nat Immunol 3(11): 999-1005.
40. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144(5): 64674.
41. Schreiber H, Wu TH, Nachman J, Kast WM. 2002. Immunodominance and tumor escape.
Semin Cancer Biol 12(1): 25-31.

37

42. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber
BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi
TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner
T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N,Kinzler KW, Zhou
S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. 2015. PD-1
blockade in tumors with mismatch-repair deficiency. New Engl J Med 372(26): 2509-20.
43. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J,
Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B,
Chan TA. 2015. Mutational landscape determines sensitivity to PD-1 blockade in non–small
cell lung cancer. Science 348(6230): 124-8.
44. Igney FH, Krammer PH. 2002. Immune escape of tumors: apoptosis resistance and tumor
counterattack. J Leukoc Biol 71(6): 907-20.
45. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP,
Mei Z, Yvon E, Weiss HL, Liu H, Rooney HM, Heslop HE, Brenner MK. 2008. Virusspecific T-cells engineered to coexpress tumor-specific receptors: persistence and antitumor
activity in individuals with neuroblastoma. Nat Med 14(11): 1264-70.
46. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O,
Liu E, Liu H, Wu MF, Gee AP, Mei Z, Rooney CM, Heslop HE, Brenner MK. 2011.
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients
with neuroblastoma. Blood 118(23): 6050-56.
47. Schiller JH, Pugh M, Kirkwood JM, Karp D, Larson M, Borden E. 1996. Eastern cooperative
group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin
Cancer Res 2(1): 29-36.
48. Meyskens FL Jr, Kopecky K, Samson M, Hersh E, Macdonald J, Jaffe H, Crowley J,
Coltman C. 1990. Recombinant human interferon gamma: adverse effects in high-risk stage I
and II cutaneous malignant melanoma. J Natl Cancer Inst 82(12): 1071.
49. Wei T, Zhang J, Qin Y, Wu Y, Zhu L, Lu L, Tang G, Shen Q. 2015. Increased expression of
immunosuppressive molecules on intratumoral and circulating regulatory T cells in nonsmall-cell lung cancer patients. Am J Cancer Res 5(7): 2190-2201.
50. Oda JMM, Guembarovski RL, Watanabe MAE. 2012. Transforming growth factor β (TGFβ) and regulatory T cells (Treg): the interface of tumor and host immunity. Eur J Clin Med
Oncol 4(1): 27-32.
51. Mahalingam J, Lin CY, Chiang JM, Su PJ, Chu YY, Lai HY, Fang JH, Huang CT, Lin YC.
2014. CD4+ T cells expressing latency-associated peptide and Foxp3 are an activated
subgroup of regulatory T cells enriched in patients with colorectal cancer. PLOS ONE 9(9):
e108554.

38

52. Hodge G, Barnawi J, Jurisevic C, Moffat D, Holmes M, Reynolds PN, Jersmann H, Hodge S.
2014. Lung cancer is associated with decreased expression of perforin, granzyme B and
interferon (IFN)-γ by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells.
Clin Exp Immunol 178(1): 79-85.
53. Knutson KL, Maurer MJ, Preston CC, Moysich KB, Goergen K, Hawthorne KM,
Cunningham JM, Odunsi K, Hartmann LC, Kalli KR, Oberg AL, Goode EL. 2015.
Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer.
Cancer Immunol Immunother 64(12): 1495-1504.
54. Kalinski P. 2012. Regulation of immune responses by prostaglandin E2. J Immunol 118(1):
21-8.
55. Strasser A, Jost PJ, Nagata S. 2009. The many roles of FAS receptor signaling in the immune
system. Immunity 20(2): 180-92.
56. Mockler MB, Conroy MJ, Lysaght J. 2014. Targeting T cell immunometabolism for cancer
immunotherapy; understanding the impact of the tumor microenvironment. Front Oncol 4:
107.
57. Egeblad M, Ewald AJ, Askautrud HA, Truitt ML, Welm BE, Bainbridge E, Peeters G,
Krummel MF, Werb Z. 2008. Visualizing stromal cell dynamics in different tumor
microenvironments by spinning disk confocal microscopy. Dis Model Mech 1(2-3): 155–67.
58. Carraro F, Pucci A, Pellegrini M, Pelicci PG, Baldari CT, Naldini A. 2007. p66Shc is
involved in promoting HIF-1alpha accumulation and cell death in hypoxic T-cells. J Cell
Physiol 211(2): 439-47.
59. Makino Y, Nakamura H, Ikeda E, Ohnuma K, Yamauchi K, Yabe Y, Poellinger L, Okada Y,
Morimoto C, Tanaka H. 2003. Hypoxia-inducible factor regulates survival of antigen
receptor-driven T cells. J Immunol 171(12): 6534-40.

39

